The proposal would involve three components.

omponent 1: Establish a drug testing agency with a number of drug testing sites in capital cities and regional hubs. The number of drug testing sites would be as follows.

This proposal would legalise the production and sale of recreational cannabis in Australia through a tightly regulated model, as follows.

This proposal would legalise the production and sale of recreational cannabis in Australia through a tightly regulated model, as follows.

This proposal would legalise the production and sale of recreational cannabis in Australia through a tightly regulated model, as follows.

This proposal has two components to establish medically supervised injecting centres.

The Commonwealth Government would provide dedicated funding to state and territory governments to fund the dispensing fees for all patients receiving opioid dependence treatment (methadone, buprenorphine and buprenorphine‐naloxone) and any associated administration costs.

The dispensing fee funding would be a standardised amount paid by states and territories to dosing point sites (mostly community pharmacies) for each dose of opioid dependence treatment.

The Commonwealth Government would provide dedicated funding to state and territory governments to fund the dispensing fees for all patients receiving opioid dependence treatment (methadone, buprenorphine and buprenorphine‐naloxone) and any associated administration costs.

The dispensing fee funding would be a standardised amount paid by states and territories to dosing point sites (mostly community pharmacies) for each dose of opioid dependence treatment.

The Commonwealth Government would provide dedicated funding to state and territory governments to fund the dispensing fees for all patients receiving opioid dependence treatment (methadone, buprenorphine and buprenorphine‐naloxone) and any associated administration costs.

The dispensing fee funding would be a standardised amount paid by states and territories to dosing point sites (mostly community pharmacies) for each dose of opioid dependence treatment.

The Commonwealth Government would provide dedicated funding to state and territory governments to fund the dispensing fees for all patients receiving opioid dependence treatment (methadone, buprenorphine and buprenorphine‐naloxone) and any associated administration costs.

The dispensing fee funding would be a standardised amount paid by states and territories to dosing point sites (mostly community pharmacies) for each dose of opioid dependence treatment.

The proposal would reduce the Pharmaceutical Benefits Schedule (PBS) general patient co-payment to $30 on 1 January 2023. Following that the co-payment would continue to be indexed by the consumer price index on 1 January each year.